BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25164234)

  • 1. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
    Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
    BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.
    Palmerini E; Jones RL; Setola E; Picci P; Marchesi E; Luksch R; Grignani G; Cesari M; Longhi A; Abate ME; Paioli A; Szucs Z; D'ambrosio L; Scotlandi K; Fagioli F; Asaftei S; Ferrari S
    Acta Oncol; 2018 Jul; 57(7):958-964. PubMed ID: 29533113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
    Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
    Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
    Raciborska A; Bilska K; Drabko K; Chaber R; Pogorzala M; Wyrobek E; Polczyńska K; Rogowska E; Rodriguez-Galindo C; Wozniak W
    Pediatr Blood Cancer; 2013 Oct; 60(10):1621-5. PubMed ID: 23776128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
    Ueda Y; Miyatake T; Nagamatsu M; Yamasaki M; Nishio Y; Yoshino K; Fujita M; Tsutsui T; Enomoto T; Kimura T
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):259-63. PubMed ID: 23880598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
    Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E
    Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
    Ushijima K; Kamura T; Tamura K; Kuzuya K; Sugiyama T; Noda K; Ochiai K
    Int J Clin Oncol; 2013 Feb; 18(1):126-31. PubMed ID: 22127346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
    Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
    Lee EM; Rha SY; Lee J; Park KH; Ahn JH
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
    Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
    Oncologist; 2012; 17(3):321. PubMed ID: 22363068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
    Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
    El Weshi A; Memon M; Raja M; Bazarbashi S; Rahal M; El Foudeh M; Pai C; Allam A; El Hassan I; Ezzat A
    Am J Clin Oncol; 2004 Oct; 27(5):529-34. PubMed ID: 15596925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
    Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
    Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
    Argiris A; Buchanan A; Brockstein B; Kolesar J; Ghebremichael M; Pins M; Hahn K; Axelrod R; Forastiere A
    Cancer; 2009 Oct; 115(19):4504-13. PubMed ID: 19634157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.
    Kebudi R; Cakir FB; Gorgun O; Agaoglu FY; Darendeliler E
    Pediatr Hematol Oncol; 2013 Apr; 30(3):170-7. PubMed ID: 23484903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
    Qi WX; He AN; Tang LN; Shen Z; Lin F; Yao Y
    Jpn J Clin Oncol; 2012 May; 42(5):427-31. PubMed ID: 22450929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
    Salah S; To YH; Khozouz O; Ismail T; Yaser S; Alnsour A; Shahin O; Sultan I; Abuhijlih R; Halalsheh H; Abuhijla F; Lewin J
    Clin Transl Oncol; 2021 Apr; 23(4):757-763. PubMed ID: 32761317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy in patients with refractory Ewing sarcoma].
    Raciborska A; Bilska K; Drabko K; Rogowska E; Chaber R; Pogorzała M; Wyrobek E; Połczyńska K; Rodriguez-Galindo C; Woźniak W
    Med Wieku Rozwoj; 2013; 17(2):117-25. PubMed ID: 23988368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.